Augurix is in the business of screening, diagnosing and monitoring one of the most under-diagnosed medical conditions worldwide: Celiac Disease.
The proprietary diagnostic platform enables seamless and rapid screening at the point of care, from whole blood, serum, plasma or saliva - and in just 10 minutes.
Swiss Startups Tackling Corona Virus - COVID-19 (venturelab.swiss)
Launch of the first rapid test for COVID-19 on the Swiss market (startupticker.ch)
Attraktive Engagements bei Start-ups (startupticker.ch)
Australien market open for Augurix (startupticker.ch)
Augurix raises CHF 3 million (startupticker.ch)
Augurix, ETHZ and University of Zürich to initiate joint research programme (startupticker.ch)
Augurix: excellent results of new clinical study (startupticker.ch)
'Debiopharm /Valais Award' for Augurix (startupticker.ch)
Frost & Sullivan Award Commends Augurix for its Unique Simtomax Test for Celiac Disease (startupticker.ch)